Abstract
Evaluation of the in vitro bee venom release and skin absorption from bioadhesive gel formulation
Highlights
Topical and transdermal drug delivery are one of the most suitable alternative, non-invasive routes for administration of drugs in clinical practice mainly due to the increased patient compliance and reduced systemic drug side effects
The aim of this study was to evaluate the stability of crude BV as an active ingredient, as well as to evaluate the in vitro release and skin absorption of BV from a designed topical gel formulation
The stability of BV was determined by a modified HPLC method (Rybak-Chmielewska and Szczêsna, 2004) using melittin (Sigma, USA) as an external standard (Agilent Technologies 1200 Series; Restek Ultra C18 column; gradient elution with 0.1% trifluoroacetic acid (TFA) in water and 0.1% TFA in acetonitrilewater 80:20), flow rate of 2.5 mL/min, 20 μL injection volume, λ of 220 nm
Summary
Topical and transdermal drug delivery are one of the most suitable alternative, non-invasive routes for administration of drugs in clinical practice mainly due to the increased patient compliance and reduced systemic drug side effects. Many drug products applied to the skin surface may penetrate to some extent into the skin layers, where their effects are expected, as for example, topical formulations for the treatment of different local skin disorders. Significant concentrations of drug could be absorbed by the body regions close to the site of delivery, where regional effects are expected, for e.g., in the muscles, local blood vessels and articulations (Ruela et al, 2016). Autoimmune disease characterized by inflammation of joints. Bee venom (BV) contains a variety of peptides, including melittin, apamin, adolapin, the mast-cell degranulating peptide, enzymes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
